# Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

> **NCT00853021** · PHASE2 · COMPLETED · sponsor: **Jorge A. Garcia, MD** · enrollment: 26 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00853021
- **Lead sponsor:** Jorge A. Garcia, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853021, "Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00853021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*